Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.40 |
| ▸ | CDK2 | P24941 | 8/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148781 | 1.00 | CDK1 (0.41) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL30331956 | 0.86 | ADORA2A (0.50) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL946328 | 0.86 | ADORA2A (0.50) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL26349114 | 0.84 | CDK1 (0.58) | CDK1CDK2ADORA3ADORA2AADORA1 | |
| SCHEMBL29426182 | 0.81 | CDK2 (0.56) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL539356 | 0.81 | CDK2 (0.56) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL945439 | 0.80 | P2RX7 (0.45) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL29782919 | 0.80 | LMNA (0.38) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL27897027 | 0.79 | CDK2 (0.44) | CDK1CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL5196618 | 0.79 | CDK1 (0.52) | CDK1CCNA2CDK2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110903289-B | Purine-aminomethyl-pyridone derivative, preparation method and application thereof | 四川大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-110903289-A | Purine-aminomethyl-pyridone derivative, preparation method and application thereof | 四川大学 | 2020-03-24 | — | — | CN | disclosed |
| WO-2011078795-A1 | BRIDGED MORPHOLINO SUBSTITUTED PURINES | S*BIO PTE LTD (SG) | 2011-06-30 | — | — | WO | disclosed |
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | CDK1 2/4885CCNA2 22/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.